Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Karuna Therapeutics Inc (NQ: KRTX )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Mar 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Karuna Therapeutics Inc

< Previous 1 2 3 4 5 6 7 8 Next >
Why Karuna Therapeutics Shares Are Trading Sharply Lower
Karuna Therapeutics Inc (NASDAQ: KRTX) shares are trading lower by 11.63% to $200.56 going into the close of Tuesday's session after the company announced a CEO transition. What Happened? 
Via Benzinga
Karuna Therapeutics Appoints Bill Meury as President and Chief Executive Officer
From Karuna Therapeutics, Inc.
Via Business Wire
Looking Into Karuna Therapeutics's Return On Capital Employed
Via Benzinga
My 3 Top Biotech Stock Picks for 2023
Biotech stocks are set to shine in 2023. 
Via The Motley Fool
Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The Helm
Neurodegenerative disorders could mean big bucks for some biotechs. 
Via Investor's Business Daily
Karuna Therapeutics: Q3 Earnings Insights
Karuna Therapeutics (NASDAQ:KRTX) reported its Q3 earnings results on Thursday, November 3, 2022 at 06:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
12 Analysts Have This to Say About Karuna Therapeutics
Within the last quarter, Karuna Therapeutics (NASDAQ:KRTX) has observed the following analyst ratings: 
Via Benzinga
Expert Ratings for Karuna Therapeutics
Analysts have provided the following ratings for Karuna Therapeutics (NASDAQ:KRTX) within the last quarter: 
Via Benzinga
Karuna Therapeutics Reports Third Quarter 2022 Financial Results and Provides General Business Updates
From Karuna Therapeutics, Inc.
Via Business Wire
What 12 Analyst Ratings Have To Say About Karuna Therapeutics
Karuna Therapeutics (NASDAQ:KRTX) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
Upgrades 
Via Benzinga
Mizuho Is Bullish On This Schizophrenia-Focused Stock, Read Why
Via Benzinga
Karuna Therapeutics to Present at the Jefferies 2022 London Healthcare Conference
From Karuna Therapeutics, Inc.
Via Business Wire
2 On-Fire Biotech Stocks That Are Crushing the Bear Market
The biotech sector is down this year, but these two biopharmaceutical stocks have delivered strong returns. 
Via The Motley Fool
Opportunities In Large Cap Growth And Small Cap
The third quarter was true 
Via Talk Markets
Biotech Stocks Well-Positioned For The Fourth Quarter
The path of interest rates is clearer for 2022 and the FED is closer to a pause early next year as it calibrates its response from a hammer approach so far. 
Via Talk Markets
PsychoGenics Announces Extension of Ongoing Drug Discovery Collaboration with Karuna Therapeutics
From PsychoGenics Inc.
Via Business Wire
Karuna Therapeutics to Present Data from the Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia at the 35th European College of Neuropsychopharmacology (ECNP) Congress
From Karuna Therapeutics, Inc.
Via Business Wire
Where Karuna Therapeutics Stands With Analysts
Over the past 3 months, 12 analysts have published their opinion on Karuna Therapeutics (NASDAQ:KRTX) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
Mainz Biomed (MYNZ) nominates two notable leaders in key areas of the diagnostics field to its Board of Directors
Via AB Newswire
7 Momentum Stocks to Buy Now for Extraordinary Gains
Momentum stocks aren't as risky as some say, and these winning stocks are strong examples for investors to consider. 
Via InvestorPlace
These Were the Five Best And Worst Performing Mid-Cap Stocks In August 2022
We have used the August return data from finviz.com to come up with the five best and worst performing mid-cap stocks in August 2022. 
Via Talk Markets
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin
The market is struggling, yet biotech stocks are acting like it's good times again. Here's why. 
Via Investor's Business Daily
Where Karuna Therapeutics Stands With Analysts
Over the past 3 months, 12 analysts have published their opinion on Karuna Therapeutics (NASDAQ:KRTX) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
What 12 Analyst Ratings Have To Say About Karuna Therapeutics
Within the last quarter, Karuna Therapeutics (NASDAQ:KRTX) has observed the following analyst ratings: 
Via Benzinga
Karuna Therapeutics to Present at Upcoming Investor Conferences
From Karuna Therapeutics, Inc.
Via Business Wire
10 Biotech Stocks Are Up 40% Or More This Year, Including Karuna, Axsome And Others
These names are benefitting from M&A, clinical data and promising regulatory actions. 
Via Investor's Business Daily
This Analyst Raises PT On Karuna Therapeutics By 100%; Wells Fargo Predicts $2,300 For This Stock
Piper Sandler boosted the price target on First Solar, Inc. (NASDAQ: FSLR) from $120 to $165. Piper Sandler analyst Kashy Harrison maintained an Overweight rating on the stock. First Solar shares rose... 
Via Benzinga
Karuna Therapeutics Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
From Karuna Therapeutics, Inc.
Via Business Wire
Coinbase, Trade Desk, H&R Block And Some Other Big Gainers From Wednesday
U.S. stocks closed higher on Wednesday following the release of inflation data. Here is the list of some big stocks moving lower in the previous session. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.